Related Experiment Video
Updated: Jul 16, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Potential protective effects of telmisartan on renal function deterioration
Andrea Remuzzi1, Giuseppe Remuzzi
1Department of Biomedical Engineering, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy. aremuzzi@marionegri.it
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|February 24, 2007
Summary
Telmisartan, an angiotensin II receptor antagonist, effectively slows kidney function decline in proteinuric kidney diseases. This drug may also improve metabolic syndrome by benefiting adipocyte metabolism and insulin resistance.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Metabolic Diseases
Background:
- Angiotensin II (Ang II) antagonism slows renal functional loss in proteinuric kidney diseases.
- Telmisartan, an Ang II receptor antagonist (AIIA), has potent, long-lasting antihypertensive effects.
- Telmisartan exhibits partial agonism of peroxisome-activated receptor-gamma, influencing metabolism.
Purpose of the Study:
- To review experimental and clinical data on telmisartan's effects on renal dysfunction.
- To explore telmisartan's potential to ameliorate renal dysfunction in metabolic syndrome.
Main Methods:
- Analysis of existing experimental and clinical studies.
- Review of data on AIIAs, focusing on telmisartan's specific actions.
Main Results:
- Sustained Ang II blockade with telmisartan can reduce renal dysfunction progression.
- Telmisartan may induce regression of renal functional and structural changes.
- Telmisartan's peroxisome-activated receptor-gamma agonism beneficially affects adipocyte metabolism, diabetes onset, and insulin resistance.
Conclusions:
- Blocking Ang II with telmisartan shows promise in managing renal dysfunction.
- Telmisartan may be a valuable therapeutic option for patients with metabolic syndrome and renal issues.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:17Factors Affecting Renal Clearance: Renal Impairment
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...